Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
University Library
Library Publications
Aurora harvest
Aurora harvest 2
Aurora harvest 3
Aurora harvest 4
Aurora harvest 5
Aurora harvest 6
Aurora harvest 7
Aurora harvest 8
Aurora submissions
Library publications
News / The University of Adelaide Libraries [1993-2001]
NEWSLINE
University of Adelaide Library News [1979-1993]
Untitled
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 21-28 of 28 (Search time: 0.003 seconds).
previous
1
2
3
next
Item hits:
Preview
Issue Date
Title
Author(s)
2010
Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: A mechanism for improved insulin sensitivity in Type 2 diabetic CML patients?
Fitter, S.
;
Vandyke, K.
;
Schultz, C.
;
White, D.
;
Hughes, T.
;
Zannettino, A.
2011
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
Kantarjian, H.
;
Giles, F.
;
Bhalla, K.
;
Pinilla-Ibarz, J.
;
Larson, R.
;
Gattermann, N.
;
Ottmann, O.
;
Hochhaus, A.
;
Radich, J.
;
Saglio, G.
;
Hughes, T.
;
Martinelli, G.
;
Kim, D.
;
Shou, Y.
;
Gallagher, N.
;
Blakesley, R.
;
Baccarani, M.
;
Cortes, J.
;
le Coutre, P.
2011
Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after Imatinib resistance is predictive of outcome during subsequent therapy
Parker, W.
;
Lawrence, R.
;
Ho, M.
;
Irwin, D.
;
Scott, H.
;
Hughes, T.
;
Branford, S.
2011
Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells
Tang, M.
;
Gonen, M.
;
Quintas-Cardama, A.
;
Cortes, J.
;
Kantarjian, H.
;
Field, C.
;
Hughes, T.
;
Branford, S.
;
Michor, F.
2012
Initial molecular response at 3 months may predict both response and event-free survival at 24 months in Imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with Nilotinib
Branford, S.
;
Kim, D.
;
Soverini, S.
;
Haque, A.
;
Shou, Y.
;
Woodman, R.
;
Kantarjian, H.
;
Martinelli, G.
;
Radich, J.
;
Saglio, G.
;
Hochhaus, A.
;
Hughes, T.
;
Muller, M.
2010
Phase III, randomized, open-label study of daily Imatinib Mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study
Cortes, A.
;
Baccarani, M.
;
Guilhot, F.
;
Druker, B.
;
Branford, S.
;
Kim, D.
;
Pane, F.
;
Pasquini, R.
;
Goldberg, S.
;
Kalaycio, M.
;
Moiraghi, B.
;
Rowe, J.
;
Tothova, E.
;
de Souza, C.
;
Rudoltz, M.
;
Yu, R.
;
Krahnke, T.
;
Kantarjian, H.
;
Radich, J.
;
Hughes, T.
2010
Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with Imatinib
White, D.
;
Dang, P.
;
Engler, J.
;
Frede, A.
;
Osborn, M.
;
Saunders, V.
;
Manley, P.
;
Zrim, S.
;
Hughes, T.
2017
Modelling predictors of molecular response to frontline imatinib for patients with chronic myeloid leukaemia
Banjar, H.
;
Ranasinghe, D.
;
Brown, F.
;
Adelson, D.
;
Kroger, T.
;
Leclercq, T.
;
White, D.
;
Hughes, T.
;
Chaudhri, N.
;
Speletas, M.
Discover
Author
12
Branford, S.
11
Hochhaus, A.
9
Kantarjian, H.
9
Radich, J.
9
White, D.
8
Cortes, J.
7
Guilhot, F.
7
Kim, D.
7
Larson, R.
7
Saglio, G.
.
next >
Subject
28
Humans
24
Pyrimidines
23
Imatinib Mesylate
22
Benzamides
22
Leukemia, Myelogenous, Chronic, B...
22
Piperazines
19
Antineoplastic Agents
14
Protein Kinase Inhibitors
13
Female
13
Male
.
next >
Date issued
15
2010 - 2017
12
2000 - 2009
1
1997 - 1999